Akili, Inc. (AKLI) Stock Price & Growth Analysis

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

Akili, Inc.

AKLI

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

34M

Medical - Healthcare Information Services

0.43USD

0.00 ( 0.25%)

Market Closed (as of Jul 01, 20:00 EDT)

Relative Strenght

Volume Buzz

-90%

Earning Acce

Yes

Dist 52w H.

65%

Overview Chart

Quote Panel

Updated April 28, 2025

1W % 1M % 3M % 1Y 83.91 %

Key Metrics

Market Cap
34.10M
Shares Outstanding
78.73M
Share in Float
23.43M
Dividende
0

Earning Date
No Data
Price Target
0.4331
Average Volume
2.30M
Beta
1.727

Range
0.1912-1.25
Industry
Medical - Healthcare Information Services
Website
https://www.akiliinteractive.com
Sector
Healthcare

Quote Panel

Updated April 28, 2025

1W % 1M % 3M % 1Y %

Key Metrics

Market Cap
Shares Outstanding
Share in Float
Dividende

Earning Date
No Data
Price Target
Average Volume
Beta

Range
Industry
Website
Sector

Fundamentals

N/A

P/E Ratio

17.50x

P/S Ratio

0.68x

P/B Ratio

0.3

Debt/Equity

-2492.0%

Net Margin

$-0.6

EPS

How AKLI compares to sector?

P/E Ratio

Fundamentals

Relative Strength

AKLI

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Relative Strength

AKLI

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$6M

1362%

2025-Revenue

$0.46

-283%

2025-EPS

$6M

45%

2025-EBITDA

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Buy

Price Target

0.00(-100.00%)

Number of analyst

Last analyst upgrade/downgrade

Morgan Stanley

initialise

Previous: Not converted

2022-12-28

Now: Equal-Weight

Forecast

Analyst rating

Last analyst upgrade/downgrade

Earnings Growth

YoY

Current

Estimates

Q2.22

N/A

-0.29
vs NA

Q3.22

N/A

-0.27
vs -0.23

Q4.22

N/A

-0.56
vs -0.25

Q1.23

N/A

-0.18
vs -0.28

Q2.23

N/A

-0.16
vs -0.29

Q3.23

N/A

-0.20
vs -0.27

Q4.23

N/A

-0.14
vs -0.56

Q1.24

N/A

-0.11
vs -0.18

Q2.24

N/A

-0.13
vs -0.16

Q3.24

N/A

-0.13
vs -0.20

Sales Growth

YoY

Current

Estimates

Q2.22

64K vs NA

Q3.22

-47%

82K vs 155K

Q4.22

-31%

111K vs 161K

Q1.23

+71%

113K vs 66K

Q2.23

+78%

114K vs 64K

Q3.23

+756%

702K vs 82K

Q4.23

+575%

749K vs 111K

Q1.24

+239%

383K vs 113K

Q2.24

+689%

900K vs 114K

Q3.24

+42%

1M vs 702K

Return on Equity

QoQ

Q2.22

+25%

0.25
vs -0.09

Q3.22

+106%

1.06
vs 0.25

Q4.22

-15%

-0.15
vs 1.06

Q1.23

-25%

-0.25
vs -0.15

Q2.23

-14%

-0.14
vs -0.25

Q3.23

-23%

-0.23
vs -0.14

Q4.23

-19%

-0.19
vs -0.23

Q1.24

-19%

-0.19
vs -0.19

Institutionnal Ownership

QoQ

Q3.22

29
vs NA

Q4.22

36
vs 29

24%

Q1.23

37
vs 36

Q2.23

35
vs 37

-5%

Q3.23

34
vs 35

-3%

Q4.23

34
vs 34

Q1.24

32
vs 34

-6%

Q2.24

36
vs 32

13%

Earnings Growth

Latest News

accesswire.com

11 hours ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AKLI, SGE on Behalf of Shareholders

accesswire.com

12 hours ago

STOCKHOLDER ALERT: The M&A Class Action Firm Investigates Merger and Expiring Tender Offer - AKLI and CALT

accesswire.com

13 hours ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AKLI, CALT on Behalf of Shareholders

prnewswire.com

15 hours ago

AKILI INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akili, Inc. - AKLI

businesswire.com

16 hours ago

Akili Announces FDA Authorization of EndeavorOTC, the First FDA Clearance of a Digital Treatment for Adults with ADHD Through a Video Game

accesswire.com

18 hours ago

AKILI INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akili, Inc. - AKLI

Company Description

0.43USD

N/A

17.50x

0.68x

0.3

-2492.0%

$-0.6

$6M

$0.46

$6M

Earnings Growth

Latest News

$6M

$0.46

$6M

Company Description

0.43USD

N/A

17.50x

0.68x

0.3

-2492.0%

$-0.6